12:00 AM
 | 
Nov 02, 2009
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Cariprazine: Preliminary Phase IIb data

Top-line data from a double-blind, placebo- and active-controlled Phase IIb trial in 732 subjects showed that 1.5, 3 and 4.5 mg/day cariprazine met the primary endpoint of significantly improving symptoms of schizophrenia as measured by change on PANSS from baseline to week 6 vs. placebo (7.5, 8.9 and 10.4 point decreases, respectively, p<0.001 for each). Each dose also met...

Read the full 275 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >